Cardiovascular benefits of SGLT2 inhibitors – not a wee effect! Retinol Binding Protein 4 is a Biomarker and Cause of Insulin Resistance and Metabolic Syndrome through Activation of the Innate and Adaptive Immune Systems Kidney disease in type 1 diabetes: lessons learned from the DCCT/EDIC Study Diabetic kidney disease: new insights into cardiovascular risk Diabetes Technology: Vices and Virtues Diabetes Hypertechnology Engaging women and clinicians with pre-pregnancy care Artificial Pancreas during Type 1 Diabetes Pregnancy Diabetes, Obesity and the Central Role of the Adipocyte in Maintaining Systemic Lipid Homeostasis Long non coding RNAs in human pancreatic beta-cells Noncoding genome function in pancreas development and disease Diabetes narratives in migrants: How careful analysis of stories can help us rise above the ontological desert of ‘behaviour change’ research Pregnancy Outcomes in Women with Diabetes – Lessons Learned from Clinical Research Innate immune-microbiota interactions protect against cachexia The role of vasoactive hormones in experimental diabetic nephropathy LEADER - More good news for the patients with type 2 diabetes SGLT2 inhibitors and renal disease The trials and tribulations of getting a drug to market The role of the Credentialled Diabetes Educator in the hospital Supersized: epigenetics in very large mammal models Finding Novel beta cell genes using the Collaborative Cross Overlap in genetic susceptibility to type 1 and type 2 - lessons from mouse models Driving and Diabetes How can registries and data improve the trajectory of care for young people with type 1 diabetes? Pharmacotherapy